Trend of A-share and Hong Kong stock innovative medicine plate this week
In the fifth week of December 2021, a total of 30 stocks in the mainland and Hong Kong innovative drugs sector rose and 17 stocks fell. Among them, Shanghai Junshi Biosciences Co.Ltd(688180) (+ 24.73%), Shanghai Junshi Biosciences Co.Ltd(688180) – U (+ 13.01%) and Rongchang bio-b (+ 10.89%). The top three declines were kaifa-b (- 72.79%), tengshengbo-b (- 15.21%) and Yaoming junuo-b (- 13.85%). This week, the A-share innovative drug sector rose 0.96%, outperforming the Shanghai and Shenzhen 300 index by 0.58pp, and biomedicine fell 0.23%. In the past six months, A-share innovative drugs fell by 18.64%, underperforming the CSI 300 index by 15.94pp, and biomedicine fell by 25.14%. This week, the innovative drug sector of Hong Kong stocks rose 0.26%, underperforming the Hang Seng Index by 0.49pp, and Hang Seng healthcare rose 0.77%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 28.33%, underperforming the Hang Seng Index by 10.28pp, and Hang Seng health care has fallen by 47.81%.
Progress of key innovative drugs in China
In December, 16 new drugs were approved for marketing in China. This week, five new drugs were approved to go on the market for the first time, namely Youcare Pharmaceutical Group Co.Ltd(688658) aldenafil citrate, Cansino Biologics Inc(688185) acyw135 group meningococcal polysaccharide conjugate vaccine, Jiangsu Hengrui Medicine Co.Ltd(600276) hengglijing tablets and darcilil hydroxyethanesulfonate tablets, and qiruiweishu capsule of Jianmin Pharmaceutical.
Progress of overseas key innovative drugs
In December, 17 new drugs were approved by FDA. This week, three new drugs were approved, namely Leo Pharma’s adbry, for the treatment of atopic dermatitis. Cabazitaxel of accord hlthcare was approved for listing on December 29. Levoketoconazole of xeris biopharma is used in the treatment of Cushing’s syndrome. In December, 10 new drugs were approved for marketing in Europe and 1 new drug was approved for marketing in Japan.
Weekly topic – small nucleic acid drugs
Nucleic acid therapy can be classified into RNA interference (RNAi) therapy, messenger RNA (mRNA) therapy, antisense oligonucleotide (ASO), small activated RNA (Sarna) therapy, regularly clustered short palindrome repeat (CRISPR) therapy and others. Aso therapy has the fastest progress and the most research projects. A total of 229 drugs are under research in the world, of which 9 drugs have been listed. Related enterprises of ASO therapy in China are Ruibo biology and Haichang biology. RNAi therapy has the second largest number, with a total of 169 drugs under research in the world, of which 4 have been listed. Relevant enterprises in China are shengnuo pharmaceutical, Ruibo biology, tengshengbo pharmaceutical, Xiangxue Pharmaceutical Co.Ltd(300147) and Qilu pharmaceutical.
Progress of global key innovative drug transactions this week
This week, there were 5 key transactions in the world, and 2 key transactions with disclosed amount. Companies involved include Yuanda pharmaceutical and German ITM, AGCO Baifa and commave.
Risk warning: expected risk of drug price reduction; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
